In Utero Enzyme Replacement Therapy for Lysosomal Storage Diseases
study id #: NCT04532047
condition: MPS I, MPS II, MPS IVA, MPS VI, Mps VII, Gaucher Disease, Type 2, Gaucher Disease, Type 3, Pompe Disease Infantile-Onset, Wolman Disease
status: Recruiting
purpose:The investigators aims to determine the the maternal and fetal safety and feasibility of in utero fetal enzyme replacement therapy in fetuses with Lysosomal Storage Diseases.
intervention: Aldurazyme (laronidase)
results: https://clinicaltrials.gov/ct2/show/results/NCT04532047
last updated: February 26, 2022
-
Mucopolysaccharidosis (MPS)https://slideplayer.com/slide/17257432/...
-
Angle-Closure Glaucoma With Attenuated Mucopolysaccharidosis Type I in a Chinese FamilyMPS I is a metabolic disease that involv...
-
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Market Research Report – Global Clinical Trials Review, H2, ...The "Mucopolysaccharidosis I (MPS I) (Hu...
-
Oxidative Stress in Mucopolysaccharidoses: Pharmacological ImplicationsAlthough mucopolysaccharidoses (MPS) are...
-
MPS and Other Similar Lysosomal DiseasesMucopolysaccharidosis (MPS) and other si...
-
36th Annual Family Conference: Nashville, TNSave the date for our 36th Annual Family...
-
Deep Intronic Variant in the ARSB Gene as the Genetic Cause for Maroteaux-Lamy Syndrome (MPS VI)Maroteaux-Lamy syndrome (MPS-VI) is a ra...